Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme (Q40010533)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

0 references

life expectancy

0 references

author name string

M Nomura

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

K Ito

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

M Miyakubo

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Y Sekine

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Y Tamura

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

N Shimizu

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

S Aoki

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

K Suzuki

8

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

publication date

6 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Prostate Cancer and Prostatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

202-209

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Screening and prostate-cancer mortality in a randomized European study

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Assessing individual risk for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Development and external validation of an extended 10-core biopsy nomogram

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

The influence of prostate size on cancer detection

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores?

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

A simple method for estimating the optimum number of prostate biopsy cores needed to maintain high cancer detection rates while minimizing unnecessary biopsy sampling.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: development of a novel pre-biopsy nomogram.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

21 January 2018

The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

31 March 2020

Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

31 March 2020

Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.62

31 March 2020

Identifiers

10.1038/PCAN.2011.62

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40010533&oldid=2203316349"